Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 3/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 10/20 | 0.37 |
| ▸ | ITGB7 | P26010 | 10/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 5/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | PTGFR | P43088 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4046036 | 0.94 | P2RX7 (0.36) | P2RX7ITGA4ITGB7ITGB1CTSK | |
| SCHEMBL4041712 | 0.93 | ITGA4 (0.40) | ITGA4ITGB7ITGB1CTSK | |
| SCHEMBL4047305 | 0.90 | P2RX7 (0.37) | P2RX7ITGA4ITGB7ITGB1CTSK | |
| SCHEMBL4041436 | 0.89 | ALDH1A1 (0.39) | P2RX7ITGA4ITGB7ITGB1 | |
| SCHEMBL4043833 | 0.89 | F10 (0.36) | P2RX7ITGA4ITGB7ITGB1CTSK | |
| SCHEMBL4044695 | 0.87 | CTSK (0.36) | CTSK | |
| SCHEMBL4047239 | 0.84 | CTSK (0.34) | P2RX7CTSK | |
| SCHEMBL4045552 | 0.83 | ITGB3 (0.37) | P2RX7ITGA4ITGB7ITGB1CTSK | |
| SCHEMBL4045912 | 0.83 | ITGA4 (0.34) | P2RX7ITGA4ITGB7ITGB1CTSK | |
| SCHEMBL4040539 | 0.83 | MC4R (0.41) | P2RX7ITGA4ITGB7ITGB1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| EP-1370561-B1 | TETRAHYDRO-PYRAZINO[1,2-A]INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS | HOFFMANN LA ROCHE (CH) | 2009-02-11 | — | — | EP | disclosed |
| US-6844345-B2 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-01-18 | — | — | US | disclosed |
| US-20020169163-A1 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169163-A1 | Piperazine derivatives | GPR119, SLC5A2, DPP4 | P2RX7 1129/4885ITGA4 4811/4885ITGB7 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.